ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,415
-0,04%
Bitcoin
70 266,97
0,19%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lyra Therapeutics Inc (LYRA)

  7. Lyra Therapeutics Inc (LYRA) Actualités

LYRA

Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LYRA
DateHeureSourceTitreSymboleSociété
21/05/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
21/05/202415h14GlobeNewswire Inc.Lyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalNASDAQ:LYRALyra Therapeutics Inc
06/05/202413h59GlobeNewswire Inc.Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
30/04/202422h04GlobeNewswire Inc.Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
26/04/202422h51GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
21/03/202421h01GlobeNewswire Inc.Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
01/03/202422h01GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
15/02/202415h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
13/02/202422h34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
01/02/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
07/11/202322h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
07/11/202322h01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
16/10/202313h00GlobeNewswire Inc.Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal OfficerNASDAQ:LYRALyra Therapeutics Inc
12/09/202313h00GlobeNewswire Inc.Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus SurgeryNASDAQ:LYRALyra Therapeutics Inc
01/09/202322h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LYRALyra Therapeutics Inc
29/08/202313h00GlobeNewswire Inc.Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
08/08/202322h01GlobeNewswire Inc.Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
13/07/202313h30GlobeNewswire Inc.Lyra Therapeutics to Present at William Blair Virtual Biotechnology ConferenceNASDAQ:LYRALyra Therapeutics Inc
13/07/202300h36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LYRALyra Therapeutics Inc
10/07/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LYRALyra Therapeutics Inc
07/07/202322h44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LYRALyra Therapeutics Inc
28/06/202322h07Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:LYRALyra Therapeutics Inc
28/06/202322h06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LYRALyra Therapeutics Inc
26/06/202323h40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LYRALyra Therapeutics Inc
15/06/202322h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LYRALyra Therapeutics Inc
09/06/202322h21Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LYRALyra Therapeutics Inc
02/06/202313h30GlobeNewswire Inc.Lyra Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:LYRALyra Therapeutics Inc
01/06/202313h29GlobeNewswire Inc.Lyra Therapeutics Announces Closing of $50.0 Million Private PlacementNASDAQ:LYRALyra Therapeutics Inc
26/05/202313h57GlobeNewswire Inc.Lyra Therapeutics Announces $50.0 Million Private PlacementNASDAQ:LYRALyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LYRA

Dernières Valeurs Consultées

NASDAQI
BSJM
Invesco BulletShares 202...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés